These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

177 related items for PubMed ID: 7498260

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Effects of the cannabinoid CB(1) receptor antagonist, SR141716A, after Delta(9)-tetrahydrocannabinol withdrawal.
    Beardsley PM, Martin BR.
    Eur J Pharmacol; 2000 Jan 03; 387(1):47-53. PubMed ID: 10633159
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. (R)-Methanandamide and delta9-tetrahydrocannabinol-induced operant rate decreases in rats are not readily antagonized by SR-141716A.
    Järbe TU, Lamb RJ, Liu Q, Makriyannis A.
    Eur J Pharmacol; 2003 Apr 11; 466(1-2):121-7. PubMed ID: 12679148
    [Abstract] [Full Text] [Related]

  • 7. Delta(9)-tetrahydrocannabinol and synthetic cannabinoids prevent emesis produced by the cannabinoid CB(1) receptor antagonist/inverse agonist SR 141716A.
    Darmani NA.
    Neuropsychopharmacology; 2001 Feb 11; 24(2):198-203. PubMed ID: 11120402
    [Abstract] [Full Text] [Related]

  • 8. Opioid and cannabinoid modulation of precipitated withdrawal in delta(9)-tetrahydrocannabinol and morphine-dependent mice.
    Lichtman AH, Sheikh SM, Loh HH, Martin BR.
    J Pharmacol Exp Ther; 2001 Sep 11; 298(3):1007-14. PubMed ID: 11504797
    [Abstract] [Full Text] [Related]

  • 9. Dependence on delta 9-tetrahydrocannabinol: studies on precipitated and abrupt withdrawal.
    Aceto MD, Scates SM, Lowe JA, Martin BR.
    J Pharmacol Exp Ther; 1996 Sep 11; 278(3):1290-5. PubMed ID: 8819514
    [Abstract] [Full Text] [Related]

  • 10. Activation of the cannabinoid receptor by delta 9-tetrahydrocannabinol reduces gamma-aminobutyric acid uptake in the globus pallidus.
    Maneuf YP, Nash JE, Crossman AR, Brotchie JM.
    Eur J Pharmacol; 1996 Jul 18; 308(2):161-4. PubMed ID: 8840127
    [Abstract] [Full Text] [Related]

  • 11. The cannabinoid CB1 antagonist N-piperidinyl-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl) -4-methylpyrazole-3-carboxamide (SR-141716A) differentially alters the reinforcing effects of heroin under continuous reinforcement, fixed ratio, and progressive ratio schedules of drug self-administration in rats.
    Solinas M, Panlilio LV, Antoniou K, Pappas LA, Goldberg SR.
    J Pharmacol Exp Ther; 2003 Jul 18; 306(1):93-102. PubMed ID: 12660305
    [Abstract] [Full Text] [Related]

  • 12. Precipitated cannabinoid withdrawal is reversed by Delta(9)-tetrahydrocannabinol or clonidine.
    Lichtman AH, Fisher J, Martin BR.
    Pharmacol Biochem Behav; 2001 Jul 18; 69(1-2):181-8. PubMed ID: 11420084
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Reversal of SR 141716A-induced head-twitch and ear-scratch responses in mice by delta 9-THC and other cannabinoids.
    Janoyan JJ, Crim JL, Darmani NA.
    Pharmacol Biochem Behav; 2002 Jul 18; 71(1-2):155-62. PubMed ID: 11812518
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Discriminative stimulus effects of the cannabinoid antagonist, SR 141716A, in delta -sup-9-tetrahydrocannabinol-treated rhesus monkeys.
    McMahon LR, France CP.
    Exp Clin Psychopharmacol; 2003 Nov 18; 11(4):286-93. PubMed ID: 14599262
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Cannabinoids decrease acetylcholine release in the medial-prefrontal cortex and hippocampus, reversal by SR 141716A.
    Gessa GL, Casu MA, Carta G, Mascia MS.
    Eur J Pharmacol; 1998 Aug 21; 355(2-3):119-24. PubMed ID: 9760025
    [Abstract] [Full Text] [Related]

  • 20. Inhibition of improgan antinociception by the cannabinoid (CB)(1) antagonist N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A): lack of obligatory role for endocannabinoids acting at CB(1) receptors.
    Hough LB, Nalwalk JW, Stadel R, Timmerman H, Leurs R, Paria BC, Wang X, Dey SK.
    J Pharmacol Exp Ther; 2002 Oct 21; 303(1):314-22. PubMed ID: 12235266
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.